Form 4 for STLN Starling Oncology, Inc.
Accepted 2026-05-22 17:37:58 ET · period of report 2026-05-21 · accession 0001079973-26-000725 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-22 17:37 | 2026-05-21 | STLN | Virnich Daniel | CEO | J - Other | $4.47 | -23.1K | 2.34M | -1.0% | -$103.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-21 | J | D | 23,058 | $4.47 | 2,337,166 | D | — | — | (F1) The Issuer executed the sale to cover the tax liabilities arising from the vesting of an RSU award made on May 21, 2024. |